AIM ImmunoTech (AIM) EBIT Margin (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly EBIT Margin came in at 10118.18% in Q1 2026, up 1250057.0% YoY from N/an in Q1 2025, and up 28.02% on a QoQ basis from 14057.14% in Q4 2025.
AIM ImmunoTech (AIM) EBIT Margin (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of EBIT Margin data on file, last reported at 10118.18% in Q1 2026.
- Quarterly EBIT Margin rose 1250057.0% year-over-year to 10118.18% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10926.6% (up 116724.0% YoY) and the FY2025 annual result came in at 13254.55%, down 162396.0% from the prior year.
- EBIT Margin advanced to 10118.18% in Q1 2026, from 14057.14% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 7388.0% in Q2 2024 to a low of 31052.38% in Q3 2022.
- A 5-year average of 14209.98% and a median of 13002.38% in 2023 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin plunged 1914632 bps — and 2023, when it soared 1331977 bps.
- Tracing AIM's EBIT Margin over 5 years: stood at 9921.43% in 2022, then tumbled by 117 bps to 21544.62% in 2023, then jumped by 40 bps to 13011.11% in 2024, then slipped by 8 bps to 14057.14% in 2025, then advanced by 28 bps to 10118.18% in 2026.
- The last three EBIT Margin figures came in at 10118.18% (Q1 2026), 14057.14% (Q4 2025), and 9411.54% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.53 Bn | 130.68 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.34 Bn | 78.35 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.67 Bn | 59.48 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.03 Bn | 36.94 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.78 Bn | 27.47 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.81 Bn | 9.42 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.21 Bn | 26.05 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 26.99 Bn | 26.15 Bn | - | 19.75% |
| 10 | AIM ImmunoTech | 4.36 Mn | -5.61 Mn | 21,000.00 | -13,511.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13,511.54% |
| Mar 31, 2026 | -10,118.18% |
| Dec 31, 2025 | -14,057.14% |
| Sep 30, 2025 | -9,411.54% |
| Jun 30, 2025 | -10,584.00% |
| Mar 31, 2025 | -22,618.75% |
| Dec 31, 2024 | -13,011.11% |
| Sep 30, 2024 | -12,825.71% |
| Jun 30, 2024 | -7,388.00% |
| Mar 31, 2024 | -14,335.00% |
| Dec 31, 2023 | -21,544.62% |
| Sep 30, 2023 | -17,732.61% |
| Jun 30, 2023 | -13,002.38% |
| Mar 31, 2023 | -8,765.31% |
| Dec 31, 2022 | -9,921.43% |
| Sep 30, 2022 | -31,052.38% |
| Jun 30, 2022 | -15,650.00% |
| Mar 31, 2022 | -9,551.52% |
| Dec 31, 2021 | -14,890.00% |
| Sep 30, 2021 | -11,906.06% |